DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

ADX-324

Generic Name: ADX-324

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Efficacy, Safety, PK, PD and HRQoL of 2 Dose Levels and Regimens of ADX-324 in Preventing HAE Attacks Compared With Placebo in Participants With Type 1 and Type II HAE

Phase 3

Not yet recruiting

Posted: 2025/05/07

Sponsor:ADARx Pharmaceutical...

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Phase 1

Recruiting

Posted: 2023/01/20

Sponsor:ADARx Pharmaceutical...

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

AbbVie and ADARx Form $335 Million Collaboration to Develop Next-Generation siRNA Therapies

11 days ago

AbbVie has invested $335 million upfront in a strategic collaboration with ADARx Pharmaceuticals to develop small interfering RNA therapeutics across neuroscience, immunology, and oncology.

Major Advances in Angioedema Pipeline: Intellia's Gene Therapy Enters Phase 3 as Multiple Companies Race for Novel Treatments

3 months ago

Intellia Therapeutics has initiated Phase 3 trials for NTLA-2002, a groundbreaking CRISPR-based gene therapy for hereditary angioedema, with potential U.S. launch targeted for 2027.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy